A Painful Ulcer That Worsens After Debridement

A rapidly enlarging exquisitely painful leg ulcer with a violaceous undermined border worsens dramatically after sharp debridement. Cultures are repeatedly negative and antibiotics have not helped. Pyoderma gangrenosum with pathergy is likely, but necrotizing infection, vascular ulcer, vasculitis, malignancy, and factitial injury must be excluded before immunosuppression.

Case focus#

The decision is to stop nonessential traumatic debridement, obtain edge biopsy and cultures for exclusion, and coordinate dermatology-led treatment. Missing infection can be fatal, while repeated surgery in true pyoderma can expand the lesion and cause major tissue loss.

This analysis concentrates on the opening phase: building a usable problem representation, recognizing time-sensitive threats, and choosing the safest next action before diagnostic certainty is available.

Problem representation#

The useful representation is not a label alone. It combines the tempo of the problem, the setting, the physiologic or functional threat, the evidence already available, and the important information that is still missing. For this pyoderma gangrenosum analysis, the working frame must remain broad enough to compare Pyoderma gangrenosum, Necrotizing or deep infection, Vasculitic ulcer, Arterial or venous ulcer without allowing a familiar first impression to become an untested conclusion.

The setting materially changes the plan: A hospital dermatology service with wound care, tissue culture and biopsy, pain management, rheumatology or gastroenterology, and surgical consultation.. Available monitoring, access to consultation, travel time, record continuity, and the reliability of follow-through alter what counts as a safe next step. A plan that is reasonable in a continuously monitored environment may be unsafe when results return after discharge or urgent reassessment is difficult.

Immediate safety priorities#

• Necrotizing infection physiology: Shock, crepitus, anesthesia, rapidly spreading toxicity, or gas requires immediate surgical action.
• Sepsis or immune suppression: Fever, hypotension, neutropenia, or deep infection risk requires cultures and urgent treatment.
• Vascular compromise: Absent pulses, critical ischemia, massive edema, or thrombosis changes wound strategy.
• Rapid expansion or uncontrolled pain: Hours-to-days progression, major bleeding, or inability to manage pain requires admission and expert review.

These findings are action signals rather than diagnostic shortcuts. They determine the pace of stabilization, consultation, and escalation while the causal analysis continues in parallel.

Prioritized differential diagnosis#

Pyoderma gangrenosum#

What supports it. Severe pain, rapidly progressive ulcer, undermined border, pathergy, and associated inflammatory disease support PG.

What argues against it or keeps uncertainty open. A proven pathogen or occlusive vascular cause argues against primary PG.

Discriminating next step. Use expert clinical assessment and biopsy for exclusion, not a single diagnostic histology.

Necrotizing or deep infection#

What supports it. Systemic toxicity, gas, tissue anesthesia, positive deep cultures, and rapid fascial spread support infection.

What argues against it or keeps uncertainty open. Stable physiology and repeated negative deep evaluation lower probability.

Discriminating next step. Do not delay surgery when clinical necrotizing infection is credible.

Vasculitic ulcer#

What supports it. Palpable purpura, livedo, systemic organ findings, and vessel inflammation support vasculitis.

What argues against it or keeps uncertainty open. Neutrophilic inflammation without vessel-wall injury, palpable purpura, or systemic vasculitic organs favors pyoderma over a vasculitic ulcer.

Discriminating next step. Biopsy an appropriate fresh edge with direct immunofluorescence when indicated.

Arterial or venous ulcer#

What supports it. Pulse deficit, pressure pattern, edema, and venous distribution support vascular disease.

What argues against it or keeps uncertainty open. Dramatic pathergy and a violaceous undermined border are less typical of a purely arterial or venous ulcer and favor pyoderma.

Discriminating next step. Perform vascular assessment before compression or aggressive procedures.

Malignancy, drug, or factitial ulcer#

What supports it. Atypical chronicity, exposed agent, pathologic cells, or geometric pattern supports another cause.

What argues against it or keeps uncertainty open. A coherent inflammatory phenotype with pathergy and no malignant cells, culprit drug, or geometric injury pattern lowers these alternative causes.

Discriminating next step. Use pathology, medication review, and trauma-informed assessment.

The differential is ranked but not closed. Probability, consequence of delay, reversibility, and test burden are considered together. A dangerous alternative can deserve early exclusion even when it is not the statistically most likely explanation.

Evidence-gathering strategy#

• Document tempo, pain, border, pathergy, and distribution. Ulcer tempo, pain severity, border morphology, distribution, and enlargement after trauma determine how strongly the presentation supports pyoderma. Interpretation: Rapid worsening after trauma is a high-value clue.
• Assess systemic toxicity and vascular status. Vitals, fascia, perfusion, pulses, edema, and neurologic findings protect against missed emergencies. Interpretation: Shock, crepitus, anesthesia, rapidly spreading erythema, absent pulses, or worsening perfusion keeps infection or ischemia dominant over pyoderma.
• Deep cultures and targeted infection testing. Bacterial, fungal, and mycobacterial studies are selected by host and exposure. Interpretation: Negative superficial swabs cannot exclude deep bacterial, fungal, or mycobacterial infection before immunosuppression.
• Edge biopsy for histology and exclusions. Biopsy seeks neutrophilic pattern, vasculitis, malignancy, and organisms. Interpretation: Neutrophilic histology supports pyoderma only after biopsy has also addressed vasculitis, malignancy, and organisms.
• Screen associated disease. Bowel symptoms, arthritis, blood counts, protein studies, and medication history identify linked conditions. Interpretation: An association may guide systemic therapy and surveillance.

Tests are selected because they can change a decision, not because a broad panel feels comprehensive. Results are interpreted with their timing, pretest probability, measurement limitations, recent treatment, and the possibility that an apparently reassuring value was obtained too early or under the wrong conditions.

Progressive course and interpretation#

Biopsy shows neutrophilic inflammation without vasculitis or malignancy and deep cultures remain negative. Imaging and serial systemic assessments do not support necrotizing infection. The team begins immunomodulatory therapy, atraumatic wound care, and evaluation for inflammatory bowel, arthritis, and hematologic associations.

The trajectory is evidence. Improvement after an intervention may support a mechanism without proving it, while nonresponse should prompt a check of the diagnosis, delivery of the intervention, timing, adherence, and competing pathology. Discordant data should be explained rather than averaged away.

Management reasoning#

• Stop avoidable traumatic debridement. Pathergy can expand true PG, though surgery remains necessary for confirmed necrotizing infection.
• Begin atraumatic wound and pain care. Nonadherent dressings, gentle cleansing, edema strategy, and analgesia protect function.
• Use expert-directed anti-inflammatory therapy. Topical, systemic corticosteroid, calcineurin, biologic, or other therapy reflects severity and comorbidity.
• Treat associated disease and infection. Inflammatory bowel, arthritis, hematologic disease, and secondary infection need coordinated management.
• Reconsider reconstruction only after control. Grafting or closure requires quiescent disease, immunologic planning, and pathergy precautions.

Management remains proportional to severity and uncertainty. It includes explicit monitoring targets, foreseeable adverse effects, and stop or escalation conditions. Exact drug selection, dosing, and procedure details depend on verified individual factors, current local protocols, contraindications, and the responsible treating team; the analytical value here is the decision structure and its guardrails.

Communication and shared decisions#

Explain that the immune system can drive a severe ulcer and that trauma may enlarge it, but tests are still needed to exclude infection and other diseases. Validate pain, photograph with consent, and align wound, dermatology, and surgical instructions.

The communication task includes what is known, what remains uncertain, why the next step is recommended, what alternatives exist, and which change should trigger urgent reassessment. Teach-back, qualified interpretation when needed, accessible formats, and a named owner for pending results turn information into a safer plan.

Continuity and safety net#

• Seek emergency care for fever, shock, crepitus, rapidly spreading redness, new numbness, or loss of limb perfusion.
• Stop unplanned sharp debridement and contact dermatology if the ulcer expands after procedures.
• Report medication infection symptoms, bleeding, uncontrolled pain, or new bowel or joint symptoms promptly.
• Use one shared wound plan across emergency, home health, surgery, and dermatology to prevent contradictory care.

Follow-through is verified, not assumed. The record should identify who receives each pending result, the time window for reassessment, the contingency if contact fails, and the clinical or functional outcome that will show whether the plan is working.

Equity and systems analysis#

Severe wounds can trigger stigmatizing assumptions about hygiene, drug use, or self-injury, especially on darker skin where border color is described differently. Use morphology and tempo, provide dressing access, and avoid punitive bedside procedures.

Access conditions belong in the causal model. Transportation, medication cost, work schedules, caregiving, health literacy, language, disability access, digital connectivity, and prior experiences of care can alter both the observed presentation and the feasibility of the plan. Addressing those constraints improves diagnostic validity as well as fairness.

Reasoning capabilities demonstrated#

• Recognizes rapid ulcer expansion, disproportionate pain, a violaceous undermined border, pathergy after debridement, negative cultures, and antibiotic failure as a pyoderma-gangrenosum pattern.
• Urgently distinguishes necrotizing infection and vascular compromise from vasculitis, malignancy, and factitial injury before immunosuppression, using systemic trajectory rather than one visual feature.
• Stops nonessential traumatic debridement and obtains an edge biopsy plus deep cultures for exclusion, interpreting neutrophilic histology as supportive but not uniquely diagnostic.
• Coordinates dermatology-led immunomodulation, atraumatic wound care, analgesia, and evaluation for bowel, arthritis, and hematologic associations while monitoring for hidden infection.
• Aligns surgical and wound instructions, photographs only with consent, and counters hygiene, drug-use, and self-injury stigma with morphology-aware dressing and follow-up access.

Key takeaways#

• Worsening after debridement is a pathergy clue, but necrotizing infection must still be actively excluded.
• Biopsy supports exclusions and pattern recognition; no single histologic finding proves pyoderma gangrenosum.
• Atraumatic wound care, pain control, immune therapy, and associated-disease evaluation belong together.